Abstract
To investigate the expression status and the clinical implications of Girdin protein in breast cancer. The expression status of Girdin protein and clinicopathological parameters in 820 breast cancer specimens was analyzed using immunohistochemistry staining and the relationship between Girdin protein and clinicopathological parameters. The prognosis of breast cancer was subsequently determined. Girdin protein was expressed positively in 295 (35.98%) of the 820 cases examined. The expression of Girdin protein was related to histological type and CerbB2 (P = 0.001, 0.006, and 0.001, respectively). After analyzing survival rates, the cases with highly expressed Girdin protein were shown to attain a significantly more distant metastasis rate and poorer postoperative, disease-specific survival than those with none or low expressed Girdin protein (P = 0.001). In the Cox regression test, Girdin protein was detected as an independent prognostic factor (P = 0.031). Girdin protein may be a potential new distant metastasis biomarker of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R, For the International Cancer Screening Network (ICSN). Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139–46.
Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006;24(12):1932–9.
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7.
Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, Blighe K, Sharma A, Walker RA, Coombes RC, Shaw JA. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342–8.
Wang X, Yi L, Zhu Y, Zou J, Hong Y, Zheng W. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERβ and HER-2 expression. Tumori. 2011;97(2):185–90.
Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30(22):2547–57.
Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y, Takahashi M. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008;68(5):1310–8.
Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM, Ghosh P. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J. 2011;25(2):590–9.
Ling Y, Jiang P, Cui SP, Ren YL, Zhu SN, Yang JP, Du J, Zhang Y, Liu JY, Zhang B. Clinical implications for Girdin protein expression in breast cancer. Cancer Invest. 2011;29(6):405–10.
Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci. 2010;101(4):836–42.
Ghosh P, Garcia-Marcos M, Farquhar MG. GIV/Girdin is a rheostat that fine-tunes growth factor signals during tumor progression. Cell Adh Migr. 2011;5(3):237–48.
De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol. 2010;28(28):4289–92.
Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422–8.
Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2011;29(4):351–4.
Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011;108(12):5021–6.
Enomoto A, Ping J, Takahashi M. Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann NY Acad Sci. 2006;1086:169–84.
Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(17):2809–15.
Goodson WH, Moore DH, Waldman FM. Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer. J Clin Oncol. 2006;24(23):3809.
Acknowledgments
This study was supported by the grant from the China National Natural Science Foundation (No. 81102029 and 81172047).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, C., Zhang, Y., Xu, H. et al. Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol 29, 1554–1560 (2012). https://doi.org/10.1007/s12032-011-0087-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0087-6